Actinium to Announce Interim Results from Pivotal Phase 3 SIERRA Trial on Conference Call Scheduled for Monday, October 28th

- Management will be accompanied by Sergio Giralt, M.D., Chief Attending Physician, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center to present data from 50 percent enrollment in the Phase 3 trial

- Conference call and webcast scheduled to start at 12:00 PM ET on Monday, October 28, 2019

NEW YORK, Oct. 24, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") announced today that it will a host a conference call and webcast to highlight interim results from the pivotal Phase 3 SIERRA trial for its lead program, Iomab-B. The SIERRA trial (Study of Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia) is a 150-patient, randomized 1:1 pivotal Phase 3 trial that is studying Iomab-B compared to physician's choice of salvage chemotherapy in patients age 55 and above with active, relapsed or refractory AML or acute myeloid leukemia. The SIERRA trial is the only randomized Phase 3 trial to offer BMT, the only potentially curative treatment option, to this patient population.

(PRNewsfoto/Actinium Pharmaceuticals, Inc.)

The SIERRA trial reached 50 percent enrollment in July 2019. The call will highlight findings from the first 50 percent of patients in the SIERRA trial.

Conference Call and Webcast Details:
Time and Date: 12:00 PM ET on Monday, October 28th
Webcast link:
U.S./Canada Toll Free Dial-in: (855) 698-6739
Participant Dial-in: (646) 402-9440
Conference ID: 0417

About Iomab-B

Iomab-B is an ARC or Antibody Radiation-Conjugate comprised of the anti-CD45 antibody apamistamab and the radioisotope iodine-131 that is intended to be a targeted conditioning agent prior to a BMT or bone marrow transplant. Iomab-B was developed at the Fred Hutchinson Cancer Research Center and has been studied in over 300 patients in multiple hematologic indications across 12 clinical trials in addition to the ongoing SIERRA study in older patients with active, relapsed or refractory AML or Acute Myeloid Leukemia prior to patients receiving an allogeneic BMT or bone marrow transplant. Iomab-B is Actinium's lead targeting conditioning ARC in its multi-target, multi-indication targeted conditioning pipeline that includes the Iomab-B and Actimab-MDS programs for BMT and the Iomab-ACT program that will study a lower dose of Iomab-B for lymphodepletion prior to CAR-T and other cellular therapies.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARC's or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARC's is targeted conditioning, which is intended to selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, Iomab-B is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. Beyond Iomab-B, we are developing a multi-disease, multi-target pipeline of clinical-stage ARC's targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including AML or Acute Myeloid Leukemia, MDS or Myelodysplastic Syndrome MM or Multiple Myeloma. Underpinning our clinical programs is our proprietary AWE or Antibody Warhead Enabling technology platform. This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARC's and ARC combinations to bolster our pipeline and for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc. 

The information in this press release contains forward-looking statements regarding future events, including statements about Actinium's expectations regarding the terms of the offering or completion of the offering.  Actinium intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to market and other conditions, the satisfaction of customary closing conditions related to the offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Actinium will be able to complete the offering on the anticipated terms, or at all. More information about the risks and uncertainties faced by Actinium are more fully detailed under the heading "Risk Factors" in Actinium's Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Except as required by law, Actinium assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


Actinium Pharmaceuticals, Inc. 
Steve O'Loughlin
Principal Financial Officer

Hans Vitzthum
LifeSci Advisors, LLC
(617) 535-7743

Cision View original content to download multimedia:

SOURCE Actinium Pharmaceuticals, Inc.